Chung‐Han Lee

10.8k total citations · 3 hit papers
140 papers, 3.9k citations indexed

About

Chung‐Han Lee is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Chung‐Han Lee has authored 140 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Pulmonary and Respiratory Medicine, 63 papers in Molecular Biology and 53 papers in Oncology. Recurrent topics in Chung‐Han Lee's work include Renal cell carcinoma treatment (76 papers), Renal and related cancers (40 papers) and Cancer Genomics and Diagnostics (38 papers). Chung‐Han Lee is often cited by papers focused on Renal cell carcinoma treatment (76 papers), Renal and related cancers (40 papers) and Cancer Genomics and Diagnostics (38 papers). Chung‐Han Lee collaborates with scholars based in United States, South Korea and Canada. Chung‐Han Lee's co-authors include Robert J. Motzer, James J. Hsieh, Kun‐Liang Guan, Ken Inoki, Ying‐Bei Chen, A. Ari Hakimi, Martin H. Voss, Bock‐Gie Jung, Daniel R. Principe and Jessica Bauer and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Chung‐Han Lee

137 papers receiving 3.9k citations

Hit Papers

An Integrated Metabolic Atlas of Clear Cell Renal Cell Ca... 2014 2026 2018 2022 2016 2014 2020 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma
    2016 531 citations A. Ari Hakimi, Ed Reznik et al. Cancer Cell profile →
  2. TGF- : Duality of Function Between Tumor Prevention and Carcinogenesis
    2014 429 citations Chung‐Han Lee et al. profile →
  3. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
    2020 306 citations Chung‐Han Lee, Robert J. Motzer et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chung‐Han Lee United States 31 2.3k 1.5k 1.3k 1.1k 347 140 3.9k
Xiaoxiang Guan China 38 2.5k 1.1× 910 0.6× 2.0k 1.6× 1.6k 1.4× 245 0.7× 173 4.7k
Simon Pacey United Kingdom 20 2.2k 1.0× 1.1k 0.7× 1.3k 1.0× 1.7k 1.5× 194 0.6× 69 3.9k
Rafael López‐López Spain 35 1.8k 0.8× 934 0.6× 2.2k 1.7× 1.7k 1.5× 282 0.8× 242 4.5k
Anne E. Cress United States 41 2.8k 1.2× 924 0.6× 1.8k 1.4× 931 0.8× 255 0.7× 147 5.4k
David R. Shalinsky United States 27 2.3k 1.0× 1.0k 0.7× 1.7k 1.3× 1.3k 1.1× 224 0.6× 52 4.3k
Clemens Mayer Netherlands 20 2.5k 1.1× 1.7k 1.1× 1.5k 1.2× 1.2k 1.0× 277 0.8× 45 4.7k
Boe Sandahl Sørensen Denmark 37 2.7k 1.2× 1.3k 0.9× 2.0k 1.6× 1.6k 1.4× 267 0.8× 171 4.9k
Charles Massie United Kingdom 24 2.2k 0.9× 1.3k 0.9× 1.1k 0.8× 2.1k 1.8× 300 0.9× 42 4.0k
Nashat Gabrail United States 26 1.6k 0.7× 788 0.5× 2.3k 1.8× 1.1k 0.9× 291 0.8× 154 4.4k
Alastair Greystoke United Kingdom 28 1.3k 0.5× 1.3k 0.9× 2.3k 1.8× 1.4k 1.2× 189 0.5× 144 3.8k

Countries citing papers authored by Chung‐Han Lee

Since Specialization
Citations

This map shows the geographic impact of Chung‐Han Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chung‐Han Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chung‐Han Lee more than expected).

Fields of papers citing papers by Chung‐Han Lee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chung‐Han Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chung‐Han Lee. The network helps show where Chung‐Han Lee may publish in the future.

Co-authorship network of co-authors of Chung‐Han Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Chung‐Han Lee. A scholar is included among the top collaborators of Chung‐Han Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chung‐Han Lee. Chung‐Han Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ged, Yasser, Luis Contreras, Roy Elias, et al.. (2025). Multi-institutional Analysis of Immune-Oncology Combination Therapy for Metastatic MiT Family Translocation Renal Cell Carcinoma. Journal of Immunotherapy. 48(3). 113–117. 1 indexed citations
2.
Fitzgerald, Kelly N., Chung‐Han Lee, Martin H. Voss, et al.. (2024). Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial. European Urology. 86(2). 90–94. 15 indexed citations
3.
Guercio, Brendan J., Min Yuen Teo, Ashley Marie Regazzi, et al.. (2024). Associations of dietary fructose with survival of patients (pts) with metastatic cancer of the urothelium (UC) and renal cell carcinoma (RCC) on immune checkpoint blockade (ICB).. Journal of Clinical Oncology. 42(16_suppl). 4571–4571. 1 indexed citations
4.
Mantia, Charlene, Opeyemi A. Jegede, Elizabeth R. Plimack, et al.. (2024). Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214. Journal for ImmunoTherapy of Cancer. 12(7). e009495–e009495. 6 indexed citations
5.
Kotecha, Ritesh R., Andrea Knežević, Kanika Arora, et al.. (2023). Genomic ancestry in kidney cancer: Correlations with clinical and molecular features. Cancer. 130(5). 692–701. 5 indexed citations
6.
Ged, Yasser, Alejandro Sánchez, Sujata Patil, et al.. (2022). Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade. Clinical Cancer Research. 28(23). 5180–5189. 20 indexed citations
7.
Lee, Chung‐Han, Martin H. Voss, Maria I. Carlo, et al.. (2022). Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates. Journal of Clinical Oncology. 40(21). 2333–2341. 105 indexed citations
8.
Tang, Cerise, Mark Zucker, Kelly N. Fitzgerald, et al.. (2022). Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. European Urology Focus. 8(5). 1278–1288. 17 indexed citations
9.
Fitzgerald, Kelly N., Robert J. Motzer, & Chung‐Han Lee. (2022). Adjuvant therapy options in renal cell carcinoma — targeting the metastatic cascade. Nature Reviews Urology. 20(3). 179–193. 16 indexed citations
10.
Feldman, Darren R., Yasser Ged, Chung‐Han Lee, et al.. (2020). Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. Cancer. 126(24). 5247–5255. 27 indexed citations
11.
Chang, Chia‐Chen, et al.. (2017). Reversion of gold nanoparticle aggregates for the detection of Cu2+and its application in immunoassays. The Analyst. 142(24). 4684–4690. 10 indexed citations
12.
Xu, Jianing, Can G. Pham, Steven K. Albanese, et al.. (2016). Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. Journal of Clinical Investigation. 126(9). 3526–3540. 77 indexed citations
13.
Hakimi, A. Ari, Ed Reznik, Chung‐Han Lee, et al.. (2016). An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. Cancer Cell. 29(1). 104–116. 531 indexed citations breakdown →
14.
Chang, Chia‐Chen, et al.. (2014). Colorimetric detection of human chorionic gonadotropin using catalytic gold nanoparticles and a peptide aptamer. Chemical Communications. 50(92). 14443–14446. 55 indexed citations
15.
Lee, Chung‐Han. (2009). Glucose Starvation Induces Apoptosis of TSC-/- cells in a p53-dependent Glucose Starvation Induces Apoptosis of TSC-/- cells in a p53-dependent Manner.. Deep Blue (University of Michigan). 1 indexed citations
16.
Lee, Chung‐Han, Ken Inoki, Magdalena Karbowniczek, et al.. (2007). Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. The EMBO Journal. 26(23). 4812–4823. 130 indexed citations
17.
Kim, Tae Wan, Ki Young Yoon, Sang‐Ho Lee, & Chung‐Han Lee. (2007). Repair of Full-thickness Defects in the Alimentary Tract Wall with a Bovine Pericardium Patch and Glue. Journal of the Korean Surgical Society. 73(6). 449–453. 2 indexed citations
18.
Kim, Sung‐Han, et al.. (2004). One Case of Solitary Metastatic Adenocarcinoma of the Uterus in Patient with Previous Gastric Cancer Treatment.. Obstetrics & Gynecology Science. 47(2). 384–387. 1 indexed citations
19.
Shin, Dong‐Hoon, et al.. (2002). The Risk Factors of Lymphedema after Breast Cancer Surgery. Annals of Rehabilitation Medicine. 26(4). 475–479. 2 indexed citations
20.
Lee, Won Jun, et al.. (2001). Multivariate Analysis of Variables Affecting on Fetal Heart Rate.. Korean Journal of Obstetrics & Gynecology. 42(8). 1769–1776. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaoxiang Guan Breakdown of academic impact, for papers by Simon Pacey Breakdown of academic impact, for papers by Rafael López‐López Breakdown of academic impact, for papers by Anne E. Cress Breakdown of academic impact, for papers by David R. Shalinsky Breakdown of academic impact, for papers by Clemens Mayer Breakdown of academic impact, for papers by Boe Sandahl Sørensen Breakdown of academic impact, for papers by Charles Massie Breakdown of academic impact, for papers by Nashat Gabrail Breakdown of academic impact, for papers by Alastair Greystoke
Rankless by CCL
2026